Wegovy, Weight loss

Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...
As new research suggests those taking GLP-1 drugs have fewer hospitalisations for alcoholism, a leading specialist warns ...